Biotech News

Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates

Design Therapeutics (DSGN)Design Therapeutics2026-03-09 20:01 ESTEarnings

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution CARLSBAD, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc.

Design Therapeutics

GeneTAC Platform Design Therapeutics develops GeneTAC small molecules that bind genomic repeat sequences and modulate transcription. The platform is designed either to increase expression of a deficient gene or reduce expression of a toxic mutant gene. DT-216P2 DT-216P2 is being developed for Friedreich ataxia and is designed to increase...

Recent company news

DSGNDesign Therapeutics2026-08-03 12:00 EST

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

DSGNDesign Therapeutics2026-06-30 12:00 EST

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

DSGNDesign Therapeutics2026-05-28 12:00 EST

Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

DSGNDesign Therapeutics2026-05-18 11:00 EST

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

DSGNDesign Therapeutics2026-05-17 20:00 EST

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026

Stock data

Close: 14.99 USD
Market cap: 635.19M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States